Martín J M, Ricart J M, Alcácer J, Rausell N, Arana G
Department of Dermatology, Hospital Clínico Universitario, Valencia, Spain.
Lupus. 2008 Jul;17(7):676-8. doi: 10.1177/0961203307088291.
Adalimumab, an anti-tumour necrosis factor agent, especially used in the treatment of rheumatoid arthritis, has a good safety profile. One of the most common side-effects of adalimumab is the development of autoantibodies. Despite the induction of autoantibodies, the clinical presentation of immune-mediated complications upon adalimumab therapy, including a lupus-like syndrome, is very rare. We have recently evaluated a new case of adalimumab-induced lupus erythematosus.
阿达木单抗是一种抗肿瘤坏死因子药物，尤其用于治疗类风湿性关节炎，具有良好的安全性。阿达木单抗最常见的副作用之一是自身抗体的产生。尽管会诱导自身抗体产生，但阿达木单抗治疗后免疫介导并发症的临床表现，包括类狼疮综合征，非常罕见。我们最近评估了一例阿达木单抗诱导的红斑狼疮新病例。
